Takayasu Arteritis With Pulmonary Artery InvolvementNCT05388682
Treatment of Patients With Takayasu Arteritis Complicated With Pulmonary Artery Involvement
An observational study of Takayasu Arteritis With Pulmonary Artery Involvement and Percutaneous Transluminal Pulmonary Angioplasty, run by Chinese Pulmonary Vascular Disease Research Group at 1 site in China.
Trial summary
1. Evaluate the effect of medical treatment and percutaneous transluminal pulmonary angioplasty on takayasu arteritis with pulmonary artery involvement 2. evaluate the efficacy of FAPI in predicting the activity and treatment efficacy of takayasu arteritis with pulmonary artery involvement Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Takayasu Arteritis With Pulmonary Artery Involvement, Percutaneous Transluminal Pulmonary Angioplasty, PAH Targeted Medication
- What is being tested?
- Percutaneous transluminal pulmonary angioplasty
- Type of treatment
- Medical device
- How many people
- 200 participants
- Where
- 1 siteChina
- Study dates
- 19 Jan 2014to 31 Dec 2042
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: patients diagnosed with Takayasu arteries with pulmonary arteries involvement received either medical or percutaneous transluminal pulmonary angioplasty
Who may be able to join
- patients diagnosed with Takayasu arteries with pulmonary arteries involvement
Who cannot join
- Patients had pulmonary artery stenosis arising from CTEPH, fibrosing mediastinitis and congenital pulmonary artery stenosis
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, China, 100000
Zhihong Liu, doctor, 13269276067
About this study
Official title: Observation of Long Term Effect of Medical and PTPA Treatment on Patients With Takayasu Arteritis Complicated With Pulmonary Artery Involvement
- Evaluate the effect of medical treatment and percutaneous transluminal pulmonary angioplasty on takayasu arteritis with pulmonary artery involvement
- evaluate the efficacy of FAPI in predicting the activity and treatment efficacy of takayasu arteritis with pulmonary artery involvement
Read the detailed description
At baseline, FAPI and FDG are performed to evaluate the activity of takayasu arteritis with pulmonary artery involvement. FAPI is also used to predict the treatment efficacy and prognosis of takayasu arteritis with pulmonary artery involvement.
- Conditions
- Takayasu Arteritis With Pulmonary Artery Involvement, Percutaneous Transluminal Pulmonary Angioplasty, PAH Targeted Medication
- Being tested
- Percutaneous transluminal pulmonary angioplasty
- Keywords
- Percutaneous transluminal pulmonary angioplasty, Takayasu Arteritis with Pulmonary Artery Involvement
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Percutaneous transluminal pulmonary angioplastyDevice
Percutaneous transluminal pulmonary angioplasty
What is being measured
The primary outcome is the main question the study is designed to answer.
all cause death
all cause death
Measured: 2014/1/1-2042/12/31
mean pulmonary arterial pressure change
change of mean pulmonary arterial pressure after treatment
Measured: 2014/1/1-2042/12/31
pulmonary vascular resistance change
chagne of pulmonary vascular resistance after treatment
Measured: 2014/1/1-2042/12/31
6MWD change
change of six minute walk distance after treatment
Measured: 2014/1/1-2042/12/31
peak VO2 change
change of peak oxygen consumption after treatment
Measured: 2014/1/1-2042/12/31
NT-proBNP change
change of NT-proBNP after treatment
Measured: 2014/1/1-2042/12/31
RV/LV change
change of right ventricular end-diastolic diameter versus laboratory left ventricular end-diastolic diameterafter treatment
Measured: 2014/1/1-2042/12/31
CI change
change of cardiac index after treatment
Measured: 2014/1/1-2042/12/31
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 May 2022
- Study start19 Jan 2014
- Primary completion31 Dec 2042 (estimated)
- Study completion31 Dec 2042 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Takayasu Arteritis With Pulmonary Artery InvolvementStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Chinese Pulmonary Vascular Disease Research Group
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- zhihong Liu, doctor, Principal investigator, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05388682
- Sponsor's protocol ID
- TAPAI
- Status last verified
- Sep 2026
- First submitted
- 19 May 2022
- Last updated
- 22 Sep 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Observation of Long Term Effect of Medical and PTPA Treatment on Patients With Takayasu Arteritis Complicated With Pulmonary Artery Involvement
- ClinicalTrials.gov ID
- NCT05388682
- Acronym / sponsor ID
- TAPAI
- Conditions
- Takayasu Arteritis With Pulmonary Artery Involvement, Percutaneous Transluminal Pulmonary Angioplasty, PAH Targeted Medication
- Keywords
- Percutaneous transluminal pulmonary angioplasty, Takayasu Arteritis with Pulmonary Artery Involvement
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- Chinese Pulmonary Vascular Disease Research GroupUniversity, hospital or other
- Study start
- 19 Jan 2014 (actual)
- Primary completion
- 31 Dec 2042 (estimated)
- Study completion
- 31 Dec 2042 (estimated)
- First posted
- 24 May 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
- Evaluate the effect of medical treatment and percutaneous transluminal pulmonary angioplasty on takayasu arteritis with pulmonary artery involvement
- evaluate the efficacy of FAPI in predicting the activity and treatment efficacy of takayasu arteritis with pulmonary artery involvement
Detailed description
At baseline, FAPI and FDG are performed to evaluate the activity of takayasu arteritis with pulmonary artery involvement. FAPI is also used to predict the treatment efficacy and prognosis of takayasu arteritis with pulmonary artery involvement.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- patients diagnosed with Takayasu arteries with pulmonary arteries involvement received either medical or percutaneous transluminal pulmonary angioplasty
Key inclusion criteria (1 listed)
- patients diagnosed with Takayasu arteries with pulmonary arteries involvement
Key exclusion criteria (1 listed)
- Patients had pulmonary artery stenosis arising from CTEPH, fibrosing mediastinitis and congenital pulmonary artery stenosis
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Percutaneous transluminal pulmonary angioplastyPercutaneous transluminal pulmonary angioplasty | Device | – |
Primary outcome
all cause death
Time frame: 2014/1/1-2042/12/31
all cause death
mean pulmonary arterial pressure change
Time frame: 2014/1/1-2042/12/31
change of mean pulmonary arterial pressure after treatment
pulmonary vascular resistance change
Time frame: 2014/1/1-2042/12/31
chagne of pulmonary vascular resistance after treatment
6MWD change
Time frame: 2014/1/1-2042/12/31
change of six minute walk distance after treatment
peak VO2 change
Time frame: 2014/1/1-2042/12/31
change of peak oxygen consumption after treatment
NT-proBNP change
Time frame: 2014/1/1-2042/12/31
change of NT-proBNP after treatment
RV/LV change
Time frame: 2014/1/1-2042/12/31
change of right ventricular end-diastolic diameter versus laboratory left ventricular end-diastolic diameterafter treatment
CI change
Time frame: 2014/1/1-2042/12/31
change of cardiac index after treatment
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Sep 2026.
- Individual participant dataSharing planned: No
Related trials for Takayasu Arteritis With Pulmonary Artery Involvement
RecruitingObservational study
Clinical Features and Prognosis of Takayasu's Arteritis With Pulmonary Arteries Involvement
Takayasu Arteritis With Pulmonary Artery Involvement, Pulmonary Arterial Hypertension Associated With Connective Tissue Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
zhihong Liu, doctor principal investigator
Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Takayasu Arteritis With Pulmonary Artery Involvement and Percutaneous Transluminal Pulmonary Angioplasty, run by Chinese Pulmonary Vascular Disease Research Group at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 22 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Zhihong Liu, doctor (86-010-88396589, zhihongliufuwai@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
all cause death (time frame: 2014/1/1-2042/12/31). The study lists 8 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Sep 2026.